首页> Cancer chemotherapy and pharmacology.> Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

导出原文传递

翻译打印收藏纠错

第一作者： Steven Blotner

作者： Steven Blotner ^[1] ; Lin-Chi Chen ; Cristiano Ferlini ; Jianguo Zhi

作者单位： Roche Innovation Center of New York ^[1]

关键词 Idasanutlin MDM2 antagonist QT interval Concentration–QTcF

发布时间 2019-03-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer chemotherapy and pharmacology.

2018年81卷3期

597-607页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Cancer chemotherapy and pharmacology.

2018年81卷3期

597-607页

检索历史清除

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

Cancer chemotherapy and pharmacology.

相似文献

同项目论文

Cancer chemotherapy and pharmacology.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

Cancer chemotherapy and pharmacology.

相似文献

同项目论文

Cancer chemotherapy and pharmacology.

相关期刊

检索历史清除